Template:Toxoplasmosis Antibiotics: Difference between revisions
Ananvilhurtz (talk | contribs) |
(Convert to AntibioticDose with disease=Toxoplasmosis for SMW linking) |
||
| Line 1: | Line 1: | ||
====Immunocompetent==== | ====Immunocompetent==== | ||
''Antibiotics only needed if patient has severe symptoms'' | ''Antibiotics only needed if patient has severe symptoms'' | ||
* | *{{AntibioticDose|disease=Toxoplasmosis|drug=Pyrimethamine|dose=200mg PO load then 50mg PO q24hrs x 4 weeks|context=Immunocompetent with Leucovorin and Sulfadiazine|population=Adult}} AND | ||
** | **{{AntibioticDose|disease=Toxoplasmosis|drug=Leucovorin|dose=10mg PO q24hrs|context=Immunocompetent adjunct|population=Adult}} AND | ||
** | **{{AntibioticDose|disease=Toxoplasmosis|drug=Sulfadiazine|dose=1g PO q6hrs|context=Immunocompetent with Pyrimethamine|population=Adult}} | ||
====Immunosprepressed==== | ====Immunosprepressed==== | ||
* | *{{AntibioticDose|disease=Toxoplasmosis|drug=Pyrimethamine|dose=200mg PO load then 75mg PO q24hrs x 4-8 weeks|context=Immunosuppressed|population=Adult}} AND {{AntibioticDose|disease=Toxoplasmosis|drug=Leucovorin|dose=25mg PO q24hrs|context=Immunosuppressed adjunct|population=Adult}} PLUS | ||
** | **{{AntibioticDose|disease=Toxoplasmosis|drug=Sulfadiazine|dose=1500mg PO q6hrs|context=Immunosuppressed with Pyrimethamine|population=Adult}} OR | ||
** | **{{AntibioticDose|disease=Toxoplasmosis|drug=Clindamycin|dose=600mg PO or IV q6hrs|context=Immunosuppressed alt|population=Adult}} OR | ||
** | **{{AntibioticDose|disease=Toxoplasmosis|drug=Azithromycin|dose=1200mg PO q24hrs|context=Immunosuppressed alt|population=Adult}} OR | ||
**[[Atovaquone]] 1500mg PO q12hrs | **[[Atovaquone]] 1500mg PO q12hrs | ||
OR | OR | ||
* | *{{AntibioticDose|disease=Toxoplasmosis|drug=Trimethoprim-Sulfamethoxazole DS|dose=5mg/kg IV q12hrs|context=Immunosuppressed alt|display=TMP/SMX|population=Adult}} | ||
====Pregnant==== | ====Pregnant==== | ||
* | *{{AntibioticDose|disease=Toxoplasmosis|drug=Spiramycin|dose=1g PO q8hrs|context=Pregnant|population=Adult}}<ref>Paquet C, Yudin MH. Toxoplasmosis in pregnancy: prevention, screening, and treatment. J Obstet Gynaecol Can. Jan 2013;35(1):78-9.</ref> | ||
**If amniotic fluid is positive treat with 3 weeks of pyrimethamine (50 mg/day orally) + sulfadiazine (3 g/day orally in 2-3 divided doses) | **If amniotic fluid is positive treat with 3 weeks of pyrimethamine (50 mg/day orally) + sulfadiazine (3 g/day orally in 2-3 divided doses) | ||
**Alternate with a 3-week course of Spiramycin 1 g 3 times daily OR | **Alternate with a 3-week course of Spiramycin 1 g 3 times daily OR | ||
*[[Pyrimethamine]] (25 mg/day orally) and sulfadiazine (4 g/day orally) divided 2 or 4 times daily until delivery AND | *[[Pyrimethamine]] (25 mg/day orally) and sulfadiazine (4 g/day orally) divided 2 or 4 times daily until delivery AND | ||
**[[Leucovorin]] 10-25 mg/day orally to prevent bone marrow suppression | **[[Leucovorin]] 10-25 mg/day orally to prevent bone marrow suppression | ||
Revision as of 01:31, 20 March 2026
Immunocompetent
Antibiotics only needed if patient has severe symptoms
- Pyrimethamine 200mg PO load then 50mg PO q24hrs x 4 weeks AND
- Leucovorin 10mg PO q24hrs AND
- Sulfadiazine 1g PO q6hrs
Immunosprepressed
- Pyrimethamine 200mg PO load then 75mg PO q24hrs x 4-8 weeks AND Leucovorin 25mg PO q24hrs PLUS
- Sulfadiazine 1500mg PO q6hrs OR
- Clindamycin 600mg PO or IV q6hrs OR
- Azithromycin 1200mg PO q24hrs OR
- Atovaquone 1500mg PO q12hrs
OR
- TMP/SMX 5mg/kg IV q12hrs
Pregnant
- Spiramycin 1g PO q8hrs[1]
- If amniotic fluid is positive treat with 3 weeks of pyrimethamine (50 mg/day orally) + sulfadiazine (3 g/day orally in 2-3 divided doses)
- Alternate with a 3-week course of Spiramycin 1 g 3 times daily OR
- Pyrimethamine (25 mg/day orally) and sulfadiazine (4 g/day orally) divided 2 or 4 times daily until delivery AND
- Leucovorin 10-25 mg/day orally to prevent bone marrow suppression
- ↑ Paquet C, Yudin MH. Toxoplasmosis in pregnancy: prevention, screening, and treatment. J Obstet Gynaecol Can. Jan 2013;35(1):78-9.
